Craig-Hallum bullish on BioHarvest Sciences, initiates with a Buy

As previously reported, Craig-Hallum analyst Matthew Hewitt initiated coverage of BioHarvest Sciences (BHST) with a Buy rating and $15 price target The firm notes BioHarvest’s leadership in botanical synthesis enables mass production of specific plant-based molecules, allowing for numerous opportunities with minimal effort. This capability positions the company to enter multiple sectors, including the food industry, biopharma, cosmetics, and nutraceuticals, it adds. RFK Jr., as Head of HHS, is prioritizing the investigation of America’s chronic disease epidemic, targeting synthetic food additives like petroleum-based chemicals and Citrus Red No. 2. Craig-Hallum points out that BioHarvest provides solutions by designing and manufacturing natural alternatives that align with the MAHA movement’s goals. This positions BioHarvest as a key player in supporting healthier, natural food additive options, it argues.